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ABSTRACT  
Objective: To determine the effect of medical treatment on work disability in patients 
with active psoriatic arthritis, in the real world setting. 
Methods: Four hundred patients with active psoriatic arthritis commencing or switching 
to anti-TNF or conventional synthetic disease modifying anti rheumatic drugs 
(csDMARD) were recruited to a prospective, UK, multicentre, observational cohort 
study.  Work disability was measured using the work productivity and activity- specific 
health problem (WPAI-SHP) instrument and peripheral joint activity with the Disease 
Activity in Psoriatic Arthritis (DAPSA) composite measure.  
Results: Four hundred patients were recruited of whom 229 (57.25%) were working (of 
any age). Sixty two patients of working age (24%) were unemployed. At six months 
there was a 10% improvement in presenteeism (p=0.007) and 15% improvement in 
work productivity (p=0.001) aamongst working patients commenced on csDMARDs 
(n=164) versus a larger and more rapid 30% improvement in presenteeism (p<0.001) 
and 40% improvement in work productivity (p<0.001) amongst those commenced on 
anti-TNF (n=65). Clinical response was poor amongst patients commenced on a 
csDMARD (n=272) with 8.4 point improvement in DAPSA (p<0.001) versus those 
commenced on anti-TNF (n=121) who had a 36.8 point improvement (p<0.001). 
Conclusion: We report significant and clinically meaningful improvements in both 
work disability and clinical outcomes after commencement of anti-TNF in the real 
world setting. Improvements in all outcomes amongst those commencing csDMARDS 
were slower and of smaller magnitude.  
INTRODUCTION 
Prospective cohort studies have demonstrated progressive joint damage, reduced 
quality of life and high levels of disability in patients with Psoriatic Arthritis (PsA).[1-
4] There is growing evidence to indicate that early diagnosis and treatment can 
ameliorate disease activity, reduce joint damage and prevent disability.[5-8] 
 
There is increasing recognition by clinicians, patient groups and regulatory agencies of 
the importance of measuring the effect of treatment with ‘real world’ outcomes 
important to patients, thereby capturing all the ways in which disease affects the 
individual.[9, 10] When assessing the effect of treatment, outcome measures such as 
joint counts or biomarkers may not capture all aspects of disease and may even be 
discordant with patient reported outcomes, and as a result, fail to capture important 
benefits to patients.[11] Work disability has become a particularly important outcome 
in the evaluation of chronic inflammatory rheumatic disease.[12, 13] Work disability 
was ranked as a highly important outcome by patients in the European League Against 
Rheumatism (EULAR) led Psoriatic Arthritis Impact of Disease (PsAID) study.[14] 
The PsAID was developed specifically for use in PsA as a patient centred, patient 
reported outcome of impact of disease to capture all the ways in which PsA affects an 
individual. Patients ranked impacts of disease in order of importance and work was 
ranked 4th behind pain, skin and fatigue.[14] 
 
There are high rates of work disability in psoriatic arthritis.  Estimates of unemployment 
and work disability range from 20-50% and 16-39% respectively in clinical trials and 
cohort studies.[3]  Presenteeism (reduced effectiveness at work) and productivity loss 
(presenteeism plus absenteeism) have been shown to be primarily associated with 
disease activity in psoriatic arthritis raising the possibility that amelioration of active 
disease may lead to reduced work disability. [15]  
 
In the present study we set out to assess the effect of medical treatment on work 
disability in patients with active psoriatic arthritis, in an unselected population of 
patients undergoing a change in medication as part of routine clinical practice in the 
UK.  
 
METHODS  
The study design for Long Term Outcomes in Psoriatic Arthritis II (LOPAS II) has 
previously been reported.[15]  In brief, LOPAS II is a prospective, multicentre 
observational cohort study to investigate work disability in PsA and the effect of 
treatment.  Twenty-three sites across the UK participated in the study (Supplementary 
figure 1).  Four hundred patients of any age and disease duration who fulfilled the 
classification for psoriatic arthritis (CASPAR) criteria[16] and were being commenced 
on conventional synthetic Disease Modifying Anti Rheumatic Drugs (csDMARD) or 
anti-Tumour Necrosis Factor inhibitors (anti-TNF) as part of routine clinical care were 
recruited. Any patients commencing csDMARD or anti-TNF were eligible for inclusion 
including new monotherapy, combination treatment and switching agents. The sample 
size was calculated to achieve 80% power to detect the minimal clinically important 
difference of 7%[17] change in presenteeism at 5% level of significance. Patients under 
18 years and non-English speaking were excluded. Physician and patient reported 
outcome measures were collected at routine clinic appointments baseline, 3 and 6 
months with additional patient reported outcomes only by post at weeks 2 and 4.  Study 
recruitment occurred between September 2011 and April 2013.  
 Work disability was assessed with the work productivity and activity impairment 
questionnaire (WPAI) [18]. The WPAI is a six item patient reported questionnaire 
asking patients to report the degree to which they experience difficulty at work due to 
a specific health problem, in this case PsA over the preceding week. Four outcomes can 
be generated from the WPAI, expressed in percentages: 
 % Absenteeism (absence from work),  
 % Presenteeism (reduced effectiveness at work),  
 % Productivity loss (a function of both absenteeism and presenteeism) 
 % General activity impairment attributable to a specific health problem.  
The WPAI has been validated for use in rheumatoid arthritis and ankylosing spondylitis 
and the presenteeism measure by Outcome Measures in Rheumatology 
(OMERACT).[19-21]  Peripheral joint disease activity was measured using the 
composite Disease Activity in Psoriatic Arthritis (DAPSA) score, a summation of 66 
swollen and 68 tender joint count, C-reactive protein (CRP), patient global and pain 
visual analogue scores (VAS).[22] Patient reported outcomes included physical 
function with the health assessment questionnaire (HAQ), the European quality of life 
five domain questionnaire (EQ5D), dermatology quality of life index (DLQI), 
Functional Assessment of Chronic Illness Therapy Fatigue scale (FACIT), and global/ 
domain specific activity VAS scores.   
 
This study is reported in accordance with the ‘strengthening the reporting of 
observational studies in epidemiology’ (STROBE) guidelines for the reporting of 
cohort studies.[23]  
 
Statistical Analysis 
All analysis was performed using the statistical package R 2014.[24] Univariate 
comparisons between treatment groups at baseline were performed using Wilcoxon 
tests. Difference within groups was made on an intention to treat basis (excluding seven 
patients who were never issued with a prescription). Multiple imputation, based on both 
the available data and underlying temporal patterns within responses for each patient, 
was used to infer values of missing predictor data using the Amelia II package in R.[25] 
Changes in the responses over time are presented as plots of mean values by time point. 
Regression modelling was used to model rates of improvements using actual dates 
(rather than planned time points) and the effects of potential predictor variables.  
Rates of improvement, using actual dates rather than planned time points, were 
modeled using regression models with missing values in explanatory 
variables estimated using multiple imputation. P values for significance tests of 
potential differences between rates of improvement in different groups, defined by 
either by treatment or duration of disease, are obtained from including interaction terms 
to these regression models. WPAI response variables were recorded in (or categorised 
to) groups representing deciles and multivariate Poisson regression models used to 
formally assess changes over time. Differences in rates of improvements were assessed 
allowing for age, sex, disease duration, baseline HAQ, DAPSA and EQ5D. To allow 
for the expected excess of zeros in the response variables, zero-inflated Poisson (ZIP) 
models were used, with a consistent set of covariates used for both the Binomial and 
Poisson components of the model. 
RESULTS 
 
The mean age of patients was 46.8 years (sd 11.02), mean disease duration 5.8 years 
(sd 8.00), and 49.9% were female.  Two hundred and twenty six patients of working 
age patients (64%) were in work with a further ten over retirement age still working.  
Ninety two patients of working age (26%) were unemployed. Table 1 illustrates the 
baseline characteristics of all patients who were commenced on anti-TNF and 
DMARD. A supplementary file (supplementary table 1) compares baseline 
characteristics of working age employed and unemployed patients at baseline. 
Unemployed patients had worse physical function than those who were employed 
(HAQ 1.5 and 0.88 respectively, p<0.001) and worse quality of life (EQ5D 0.71 and 
0.78 respectively p<0.001).   
 
Follow up time points and loss to follow up 
Seven of the 400 patients recruited did not commence a drug and were excluded from 
the analysis. A total of 63 patients did not complete six months follow up. Forty nine 
patients became lost to follow up and a further 14 withdrew from the study (two became 
pregnant, two developed cancer, one relocated, nine cited personal reasons), two 
patients had their diagnosis changed to osteoarthritis and one patient died of an 
unrelated condition during the six months. Figure 1 illustrates the study recruitment and 
follow up, by treatment group and those included in the work analysis. There were no 
statistically significant differences in demographic or baseline disease characteristics 
between those lost to follow up and those who remained in the study. 
 
Drugs commenced during LOPAS II 
Of the 272 patients who started (including switching and step-up combination 
treatment) csDMARDS 54% started methotrexate, 30% Sulphasalazine, 12% 
Leflunomide, 1% commenced Cyclosporine, 1% Azathioprine, 1% 
Hydroxyxchloroquine and 1% combination treatment. Of the 121 who commenced 
anti-TNF (including switching and step-up combination treatment) 56% commenced 
Adalimumab, 35% Etanercept, 5% Infliximab and 4% Golimumab. The planned study 
clinical follow up was ‘per routine care’ with clinical assessment at 3 and 6 months.  
Additional patient reported questionnaires were completed at 2 and 4 weeks by post. 
There was variation in the times at which patients were seen; median and IQRs for days 
from baseline for the five time points were 14 (14-26), 28 (28-42), 98 (89-119), 196 
(179-224).  
 
Work Disability and Clinical Outcome 
One hundred and sixty four of the 272 patients commenced on csDMARD and 65 of 
the 121 commenced on anti-TNF were working (figure 1). Over six months follow up 
those commenced on csDMARDS had a 10% improvement in presenteeism (IQR 30- 
20 p=0.007) and 15% improvement in productivity loss (IQR 40 to 25 p=0.001). 
Patients commenced on anti-TNF had a 30% improvement in presenteeism (IQR 40 to 
10 p<0.001) and 40% improvement in productivity loss (IQR 50 to 10 p<0.001). 
Improvement was more rapid and of a greater magnitude amongst those commenced 
on anti-TNF (Figure 2). Although absenteeism did improve this improvement was not 
statistically significant. 
 
Clinical improvement was measured using the DAPSA composite index. Patients 
commenced on csDMARD had 8.4 point improvement (IQR 38.6 - 30.2, p<0.0001). 
Patients commenced on anti-TNF had a 36.8 point improvement (IQR 50.8 to 14.0) 
(Figure 3). Sixty five percent of those commencing anti-TNF achieved a 50% response 
in DAPSA versus 26% of those commencing csDMARD. Tables 2 and 3 summarise 
the individual changes in patient reported and clinical outcome during the course of six 
months follow up. Patients commenced on anti-TNF had achieved improvements in all 
outcomes and these improvements exceed the minimally important difference (MID) 
in global activity[26], pain[26], physical function (HAQ)[26], fatigue (FACIT)[27] and 
quality of life (EQ5D)[28] but not skin specific quality of life (DLQI)[29]. Smaller, but 
statistically significant improvements were observed amongst patients commenced on 
csDMARDS although improvements greater than the MID were only observed in 
global activity, pain, and fatigue. Change in global, pain, joint and skin specific VAS, 
HAQ, DAPSA, FACIT and DLQI amongst both groups are illustrated in Figure 3.  
 
A sub-analysis was performed to investigate whether the greater change seen in patients 
receiving anti-TNF versus csDMARD might be sensitive to baseline disease activity. 
Those starting on anti-TNF have higher disease activity and therefore may have greater 
scope for improvement. It was found that the rate of improvement of presenteeism, 
productivity loss and activity impairment in anti-TNF versus DMARD treatment was 
seen in patients with both high and low baseline disease activity.  Rates of improvement 
in absenteeism were slower amongst those with low disease activity.   
 
Work Disability –rates of change during follow up  
Given the observational nature of the study there was variance in follow up around each 
planned follow up time point. In order to assess differences in rate of change over time 
analyses were undertaken by exact time point (days). Significant decreases were found 
in all WPAI domains (absenteeism, presenteeism, productivity loss and activity 
impairment) during follow up (p<0.0001). Patients commenced on anti-TNF improved 
more rapidly than those on csDMARDS in all WPAI domains (p<0.001 for differences 
in rate of improvement).  
 
Work disability and disease duration 
Two hundred and ninety-two patients had complete recorded data for onset of disease, 
with 83 patients recorded as having disease duration <=2 years and 209 greater than 2 
years at baseline. Previously identified clinical and demographic predictor variables 
were included in the regression including age, disease duration, global and joint VAS 
scores, HAQ and employer helpfulness. [15] Patients with shorter duration had 
significantly higher activity loss (p=0.002), presenteeism (p=0.003), absenteeism 
(p<0.001) and productivity loss (p=0.008) at baseline. There was a statistically greater 
improvement in productivity loss amongst those with disease duration <2 years,  
 
 
DISCUSSION 
We report improvement in work disability, clinical and patient reported outcome 
amongst a cohort of patients in the UK commenced on anti-TNF and csDMARDS, for 
active psoriatic arthritis, as part of their routine care. Improvements in all outcomes 
were more rapid and of greater magnitude amongst those commenced on anti-TNF 
despite higher levels of baseline disease activity. Notably, gain in work productivity 
with anti-TNF was even greater with shorter duration disease. Clinical and patient 
reported outcome response to csDMARDS was poor, achieving MID improvements in 
pain/global VAS and fatigue alone. To our knowledge LOPAS II is the first study of its 
type, sufficiently powered to use work disability as the primary endpoint. 
 
There has been interest in the effect of treatment on work disability in long term 
rheumatic diseases, in particular studies comparing different classes of drug treatment. 
Many of the recent randomised controlled trials (RCT’s) of novel therapeutic agents in 
psoriatic arthritis have included work as a secondary endpoint. [30-32] Comparison of 
biological and conventional synthetic disease modifying anti-rheumatic drugs in 
rheumatoid arthritis have demonstrated reduced absenteeism, reduced sick leave, 
higher employment potential and greater levels of employment potential amongst those 
treated with biologics.[33]  The data we present in this present study describes the 
differential effect of anti-TNF and csDMARDs on patient reported work disability 
(presenteeism and productivity loss) in a well classified group of patients with psoriatic 
arthritis in the real world setting. The work disability data we report is attributable to 
psoriatic arthritis (using the WPAI-SHP) and is granular (over the last week) 
minimising recall bias. The study is further strengthened by using well defined patients 
(CASPAR criteria), multicentre recruitment across the UK, and broad inclusion criteria 
(encompassing patients of any age and disease duration) which increase the 
generalisability of the findings.  
 
Whilst there is recognition that work is an important outcome there has been debate on 
how to use the measure and interpret work data.  It has been argued that there are too 
many contextual factors to justify wider uptake of work as a disease outcome measure. 
Recognising these concerns the Outcome Measures in Rheumatology (OMERACT) 
core set of domains for psoriatic arthritis controlled trials and observational studies 
placed participation (including work) in the outer circle for further research in 2007.[34] 
The findings of this study support the view that contextual factors may have less impact 
in the context of active disease that previously thought, particularly with respect to 
measures of in work disability.[33] We have previously reported that measures of 
reduced effectiveness at work (presenteeism and productivity loss) are more strongly 
associated with disease activity than disease severity (damage) or contextual 
measures.[15] Work disability has also been found to be associated with fatigue in 
PsA.[35] Now, in this present study, as in the highly selected populations of novel 
biologic agent RCT’s, we have observed that work disability improves in parallel to 
clinical disease activity despite contextual factors. The finding that disease duration of 
<2 years is associated with more rapid improvement is of clinical interest, particularly 
because unemployment is often irreversible, and this may add to the building case for 
early intervention in newly diagnosed psoriatic arthritis. Our results support the role for 
work disability as an effective, patient centred disease outcome measure of 
participation.  
  
The clinical improvement seen after commencing anti-TNF and relative lack of 
response amongst csDMARDS in this study is striking. The effectiveness of anti-TNF 
in PsA is well established whereas studies of csDMARD are limited.[36] Many of the 
csDMARD studies were conducted before the modern era of more aggressive treatment 
with higher doses, combination therapy and a treat to target approach. The results of 
this observational cohort study has shown that amongst 272 patients commenced on 
csDMARDs,  as part of routine care, improvement in clinical, biochemical and patient 
reported measures was slow of small magnitude. As this was an observational study we 
did not influence csDMARD choice or dosing and it is possible that some of the poor 
response may be related to lower dosing, differing dose escalation regimes and 
inclusion of drugs that may be less efficacious in PsA. Finally we should also note there 
is also an ongoing trend to improvement in the csDMARD group (Figure 3) which may 
become significant with longer follow up.  
 
When interpreting the findings of this study is important to highlight certain 
methodological limitations. LOPAS II was an observational study therefore direct 
comparison cannot be made between treatment groups. Patients were recruited at a 
point of high disease activity therefore some improvement over the course of the study 
may be related to the natural relapsing remitting course of disease. It is our view this 
effect will have been small, firstly as patients commencing anti-TNF were in sustained 
flare (as part of their eligibility for anti-TNF in the National Health Service, having 
failed csDMARDS) and secondly the limited improvement seen amongst those 
commenced on csDMARDS. Finally it is important to recognise that the DAPSA is a 
measure of articular disease in PsA, rather than a composite outcome measure capturing 
all domains of disease. The DAPSA will not capture other important domains of disease 
(enthesitis, skin, dactylitis, axial involvement) except indirectly thought the global VAS 
score.  
 
In conclusion we report data from a large observational cohort study on the effect of 
medical treatment with anti-TNF or csDMARDS commenced as part of routine care on 
patient reported work disability and clinical outcome. Work disability and clinical 
outcome improved quickly to clinically significant levels amongst those commenced 
on anti-TNF despite high levels of disease activity. Improvements in work disability 
occurred more slowly and were of a smaller magnitude and clinical improvement was 
poor amongst those commenced on csDMARDS. This data supports the view that work 
disability is reversible with effective treatment of active disease in the real world 
setting. 
 
 
KEY MESSAGES 
1. Work disability in active Psoriatic Arthritis is reversible with medical treatment 
2. Clinically meaningful improvements in both work disability and clinical 
outcomes after commencement of anti-TNF.  
3. Improvements in all outcomes amongst those commencing csDMARDS were 
slower and of smaller magnitude. 
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Figure 1- Loss to follow up during study LOPAS II 
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Figure 2 
Work outcome amongst working participants commenced on anti-TNF (n=65) 
and conventional synthetic DMARD (n=164)  
 
WPAI- Work productivity activity and impairment index 
csDMARD- conventional synthetic Disease Modifying Anti-Rheumatic Drug 
anti-TNF- anti-Tumour Necrosis Factor alpha inhibitor 
  
 
Figure 3 
Clinical outcomes amongst participants commenced on anti-TNF (n=121) and 
conventional synthetic DMARD (n=272)  
 
DAPSA- Disease activity in Psoriatic Arthritis 
HAQ- Heath Assessment Questionnaire 
DLQI- Dermatology Quality of Life Index 
FACIT-F- Functional Assessment of Chronic Illness Therapy Fatigue scale 
VAS- Visual Analogue Scale 
csDMARD- conventional synthetic Disease Modifying Anti-Rheumatic Drug 
anti-TNF- anti-Tumour Necrosis Factor alpha inhibitor 
 
 
 
 
 
  
 Outcome (range) 
DMARD  
(median/ IQR) 
Anti-TNF  
(median/ IQR) 
P value 
(Wilcox) 
No. of patients (n) 272 121  
Percentage Male (%) 46.7 23.5  
Age 50.6 (41.9-60.2) 52.8 (42.9-62.3) 0.2759 
Duration 5.0 (2.0-11.0) 11.0 (3.5-18.5) <0.0001 
HAQ (0-1) 0.9 (0.5-1.5) 1.1 (0.8-1.8) 0.0116 
EQ5D (-0.11-1) 0.7 (0.6-0.9) 0.7 (0.6-0.8) 0.2469 
DLQI (0-30) 2.0 (1.0-6.0) 3.0 (1.0-6.0) 0.9685 
Pain Vas (0-100) 62.0 (42.5-81.0) 69.0 (58.0-82.0) 0.0704 
Global Vas(0-100) 65.0 (43.5-81.0) 69.0 (49.5-79.0) 0.2209 
Joint Vas(0-100) 58.0 (43.5-78.5) 67.5 (51.0-80.0) 0.0375 
Skin Vas(0-100) 30.5 (12.0-62.8) 33.0 (11.0-56.0) 0.8785 
PGA (0-5) 3.0 (2.0-4.0) 3.0 (3.0-4.0) 0.0049 
Tender joint score (0-68) 11.0 (5.0-20.0) 16.0 (11.0-25.0) <0.0001 
Swollen joint count (0-66) 5.0 (2.0-10.0) 7.0 (5.0- 12.0) <0.0001 
CRP 6.0 (2.0-16.0) 8.5 (5.0-20.0) 0.0389 
Absenteeism (%) 
(n= 164 DMARDS, 65 anti TNF) 
0.0 (149) 0.0- 8.1 0.00 (55) 0.0-9.2 0.7623 
Presenteeism (%) 
(n= 164 DMARDS, 65 anti TNF) 
30.0 (155) 10.0-60.0 40.0 (61) 20.0-60.0 0.3920 
Productivity Loss (%) 
(n= 164 DMARDS, 65 anti TNF) 
40.0 (150) 20.0-70.0 50.0 (55) 26.2-70.2 0.4906 
Activity Impairment (%) 
(n= 164 DMARDS, 65 anti TNF) 
50.0 (163) 30.0-70.0 60.0 (65) 30.0-70.0 0.0259 
 
Table 1- Baseline characteristics of 393 participants commencing DMARD or 
anti-TNF for active psoriatic arthritis 
 
Health Assessment Questionnaire (HAQ),  European Quality of Life 5 Domain Index (EQ5D),  Dermatology Life Quality Index 
(DLQI),  Visual Analogue Scale (VAS),  Patient Global Assessment (PGA), C-Reactive Protein (CRP), Disease Activity score 
Psoriatic Arthritis (DAPSA), 
Seven patients did not commence a DMARD or anti-TNF and were excluded from the analysis.  
Statistically significant differences between groups notified in bold  
  
Outcome   
(range) 
Baseline  
Median (n) 
IQR 
6 months 
Median (n) 
IQR 
P value 
(Wilcox) 
HAQ  (0-3) 1.0 (236) 0.5-1.6 0.9 (198)  0.3-1.5 0.0643 
EQ5D (-0.11-1) 0.7 (238) 0.6- 0.9 0.8 (190) 0.7- 1.0 0.0243 
DLQI (0-30) 2.0 (233) 1.0- 7.0 1.0 (188) 0.0- 3.0 <0.0001 
Pain Vas (0-100) 62.0 (234) 42.0-81.0 45.5 (189) 23.8- 70.0 <0.0001 
Global Vas (0-100) 65.0 (235) 43.3- 81.8 45.0 (189) 25.8- 69.3 <0.0001 
Joint Vas (0-100) 57.0 (227) 42.3- 79.0 47.0 (186) 24.0- 67.0 <0.0001 
Skin Vas (0-100) 32.0 (233) 12.0- 64.0 21.0 (186) 7.0-45.0 0.0009 
Fatigue (0-52) 31.0 (232) 19.8-42.0  36.0 (188) 24.0-43.0 0.0189 
Tender joint score (68) 11.0 (268) 5.0- 21.0 7.0 (263) 3.0- 18.0 0.0005 
Swollen joint count (66) 5.0 (268) 2.0- 10.0 3.0 (263) 0.0- 7.0 <0.0001 
CRP (0->100) 0.6 (259) 0.2- 1.6 0.5 (242) 0.2- 1.0 0.0228 
DAPSA 38.7 (n/a) 27.9-58.5 30.2 (n/a) 18.4- 48.5 <0.0001 
Absenteeism (%) 
(164 working of 272) 
0.0 (149) 0.0- 8.1 0.0 (145) 0.0-7.8 0.8751 
Presenteeism (%) 
(164 working of 272) 
30.0 (155) 10.0-60.0 20.0 (155) 10.0-42.5 0.0075 
Productivity Loss (%) 
(164 working of 272) 
40.0 (150) 20.0-70.0 25.0 (144) 10.0-60.0 0.0147 
Activity Impairment (%) 
(164 working of 272) 
50.0 (163) 30.0-70.0 40.0 (163) 0.0-60.0 0.0036 
 
Table 2- Clinical outcome of 272 participants commenced on DMARDS for 
active psoriatic arthritis  
Health Assessment Questionnaire (HAQ),  European Quality of Life 5 Domain Index (EQ5D),  Dermatology Life Quality Index 
(DLQI),  Visual Analogue Scale (VAS),  C-Reactive Protein (CRP), Disease Activity score Psoriatic Arthritis (DAPSA), 
N= actual number of data before imputation 
Statistically significant differences between groups notified in bold  
 
 
-  
Outcome  
(range) 
Baseline  
Median (n) IQR 
6 months  
Median (n) IQR 
P value 
(Wilcox) 
HAQ (0-3) 1.1 (101) 0.8-1.8 0.8 (80) 0. 0-1.4 0.0001 
EQ5D (-0.11-1) 0.7 (102) 0.6-0.8 0.9 (82)  0.7- 1.0 0.0002 
DLQI (0-30) 3.0 (97) 1.0-6.0 1.0 (79) 0.0-2.0 0.0002 
Pain Vas (0-100) 69.0 (97) 57.5-82.0 33.0 (83) 11.0-57.0 <0.0001 
Global Vas (0-100) 69.0 (95) 50.0-79.0 31.0 (88) 12.0-60.0 <0.0001 
Joint Vas (0-100) 68.5 (86) 51.0-80.3 32.5 (82) 10.0-49.8 <0.0001 
Skin Vas (0-100) 33.0 (95) 12.0-56.0 14.0 (82) 40.0-26.0 <0.0001 
FACIT (0-52) 28.0 (86) 17.5-38.0) 38.0 (82) 25.0-46.0 <0.0001 
Tender joint score (68) 16.0 (119) 11.0-25.0 4.0 (99) 1.0-14.0 <0.0001 
Swollen joint count (66) 7.0 (119) 5.0-12.0 1.0 (99) 0.0-3.0 <0.0001 
CRP(0->100) 0.8 (116) 0.5-1.9 0.3 (89) 0.1-0.6 <0.0001 
DAPSA 52.8 (n/a) 38.3-66.4 14.0 (n/a) 6.9-37.4 <0.0001 
Absenteeism (%) 
(65 working of 121) 
0.0 (55) 0.0-9.2 0.0 (45) 0.0-0.0 0.0415 
Presenteeism (%) 
(65 working of 121) 
40.0 (61) 20.0-60.0 10.0 (55) 0.0-30.0 <0.0001 
Productivity Loss (%) 
(65 working of 121) 
50.0 (55) 26.2-70.2 10.0 (45) 0.0-35.0 <0.0001 
Activity Impairment (%) 
(65 working of 121) 
60.0 (65) 30.0-70.0 20.00 (55) 10.0- 50.0 <0.0001 
 
Table 3- Clinical outcome during follow up of 121 patients commenced on anti-
TNF for active psoriatic arthritis 
 
Health Assessment Questionnaire (HAQ),  European Quality of Life 5 Domain Index (EQ5D),  Dermatology Life Quality Index 
(DLQI),  Visual Analogue Scale (VAS),  C-Reactive Protein (CRP), Disease Activity score Psoriatic Arthritis (DAPSA),  
N= actual number of data before imputation 
Statistically significant differences between groups notified in bold  
 
 
 
